Overview


Because of its popularity and extensive adoption by pharmaceutical businesses, Pharmaceutical Contract Development and Manufacturing contributes significantly to the entire outsourcing market. Cost-cutting challenges brought on by global economic constraints have put a lot of pressure on pharmaceutical corporations to reduce product costs. As a result, pharma companies are seeking for ways to cut manufacturing costs in order to get out of this dilemma. Contract manufacturing, as a strategic alternative, provides a number of advantages, including cost savings, increased product quality, a broader product variety, and a shorter time to market.

Pharmaceutical Contract Development and Manufacture also helps pharmaceutical businesses focus on R D and marketing by reducing the amount of time and effort spent on manufacturing. As a result, pharmaceutical contract development and production has become a widely accepted practise in recent years. Some of the major participants in this market are HAUPT Pharma AG, Abbott Laboratories, NextPharma, Catalent Pharma Solutions, Althea Technologies, Jubilant Life Sciences Limited, Royal DSM N.V., and Nipro Corp. The market is expected to grow due to the patent expiration of major therapeutic brands, rising demand for generic drugs, and the adoption of novel manufacturing technologies. Prescription pharmaceuticals, vaccinations, and over-the-counter (OTC) drugs are all generated based on discoveries from life sciences research, which has a direct impact on the pharmaceutical industry.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pharmaceutical Contract Development and Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Pharmaceutical Contract Development and Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Thermo Fisher Scientific Inc.
  • Catalent, Inc.
  • Vetter Pharma-Fertigung GmbHCo. KG.
  • Lonza Group Ltd.
  • Recipharm AB
  • Cambrex Corporation
  • Aenova Group GmbH.
  • Samsung Biologics Co., Ltd.
  • Piramal Enterprises Limited
  • Almac Group
  • Siegfried Holding AG
  • Aurobindo Pharma ltd.
  • FUJIFILM Diosynth Biotechnologies
  • WuXi Biologics (Cayman) Inc.
  • C.H. Boehringer Sohn AGCo. KG.
  • Fabbrica Italiana Sintetici S.p.A.
  • Fareva

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Service

  • Pharmaceutical Manufacturing Services
    • Pharmaceutical API Manufacturing Services
    • Pharmaceutical FDF Manufacturing Services
      • Parenteral/Injectable Manufacturing Services
      • Tablet Manufacturing Services
      • Capsule Manufacturing Services
      • Oral Liquid Manufacturing Services
      • Other Formulations Manufacturing Services
  • Drug Development Services
  • Biologics Manufacturing Services
    • Biologics API Manufacturing Services
    • Biologics FDF Manufacturing Services
  • Packaging Services

By End User

  • Large Pharmaceutical Companies
  • Small and Mid-size Pharmaceutical Companies
  • Generic Pharmaceutical Companies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Pharmaceutical Contract Development and Manufacturing Market By Service, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Pharmaceutical Contract Development and Manufacturing Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Pharmaceutical Contract Development and Manufacturing Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Pharmaceutical Contract Development and Manufacturing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Pharmaceutical Contract Development and Manufacturing Market, By Service Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical Manufacturing Services
         1.1. Pharmaceutical API Manufacturing Services
         1.2. Pharmaceutical FDF Manufacturing Services
          1.2.1. Parenteral/Injectable Manufacturing Services
          1.2.2. Tablet Manufacturing Services
          1.2.3. Capsule Manufacturing Services
          1.2.4. Oral Liquid Manufacturing Services
          1.2.5. Other Formulations Manufacturing Services
        2. Drug Development Services
        3. Biologics Manufacturing Services
         3.1. Biologics API Manufacturing Services
         3.2. Biologics FDF Manufacturing Services
        4. Packaging Services

  • 8.   Pharmaceutical Contract Development and Manufacturing Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Large Pharmaceutical Companies
        2. Small and Mid-size Pharmaceutical Companies
        3. Generic Pharmaceutical Companies

  • 9.   North America Pharmaceutical Contract Development and Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Pharmaceutical Contract Development and Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Pharmaceutical Contract Development and Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Pharmaceutical Contract Development and Manufacturing Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Catalent, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Vetter Pharma-Fertigung GmbHCo. KG.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Lonza Group Ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Recipharm AB
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cambrex Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Aenova Group GmbH.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Samsung Biologics Co., Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Piramal Enterprises Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Almac Group
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Siegfried Holding AG
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Aurobindo Pharma ltd.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. FUJIFILM Diosynth Biotechnologies
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. WuXi Biologics (Cayman) Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. C.H. Boehringer Sohn AGCo. KG.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Fabbrica Italiana Sintetici S.p.A.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Fareva
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients